GGrantIndex
← Leaderboards

Octavio Ramilo

Emory University

$12,889,369
Attributed
$23,977,339
Total exposure
11
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.9M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$37,619,395 · 13

By mechanism

R01$11,520,286 · 3
U19$10,589,521 · 5
P01$8,311,944 · 2
U01$6,270,565 · 1
R21$927,079 · 2

Most similar at Emory University

Same institution · by research overlap

Others in their field

Top investigators on “Infection

Research focus

InfectionImmune ResponseSamplingBloodChildImmuneLifeInfantResponseResearch PersonnelMorbidity - Disease RateGenesMortalityVirus DiseasesMultidisciplinaryCharacteristicsHospitalizationDesignGenetic TranscriptionEvaluationCellsShapesVaccinesImmune System

Grant awards (55)

Early life respiratory viral infections shape immune development trajectories$1,686,867
U19 · FY2025 · AI · contact PI
Resubmission: Elucidating Pediatric Sepsis by Defining Comprehensive Signatures for Diagnosis and Outcome$578,886
R01 · FY2025 · HD
Project 1$377,467
U19 · FY2025 · AI · contact PI
Administrative Core$65,515
U19 · FY2025 · AI · contact PI
Early life respiratory viral infections shape immune development trajectories$1,688,409
U19 · FY2024 · AI · contact PI
Resubmission: Elucidating Pediatric Sepsis by Defining Comprehensive Signatures for Diagnosis and Outcome$590,077
R01 · FY2024 · HD
Project 1$486,580
U19 · FY2024 · AI · contact PI
SMILE: Sickle Cell Disease Microbiologic and Immunologic Links to Health Equity$236,634
R21 · FY2024 · AI
Administrative Core$112,725
U19 · FY2024 · AI · contact PI
Early life respiratory viral infections shape immune development trajectories$1,767,642
U19 · FY2023 · AI · contact PI
Resubmission: Elucidating Pediatric Sepsis by Defining Comprehensive Signatures for Diagnosis and Outcome$586,187
R01 · FY2023 · HD
Project 1$521,453
U19 · FY2023 · AI · contact PI
SMILE: Sickle Cell Disease Microbiologic and Immunologic Links to Health Equity$222,445
R21 · FY2023 · AI
Administrative Core$92,620
U19 · FY2023 · AI · contact PI
Early life respiratory viral infections shape immune development trajectories$1,689,999
U19 · FY2022 · AI · contact PI
Resubmission: Elucidating Pediatric Sepsis by Defining Comprehensive Signatures for Diagnosis and Outcome$595,488
R01 · FY2022 · HD
Project 1$475,923
U19 · FY2022 · AI · contact PI
Administrative Core$91,422
U19 · FY2022 · AI · contact PI
High Precision System Analysis of Infant Immune Responses$1,258,393
U01 · FY2021 · AI
High Precision System Analysis of Infant Immune Responses$523,644
U01 · FY2021 · AI
High Precision System Analysis of Infant Immune Responses$1,668,904
U01 · FY2020 · AI · contact PI
High Precision System Analysis of Infant Immune Responses$526,213
U01 · FY2020 · AI · contact PI
High Precision System Analysis of Infant Immune Responses$360,758
U01 · FY2020 · AI · contact PI
Live Attenuated RSV Vaccine with Optimized Safety and Immunogenicity$1,557,469
P01 · FY2019 · AI
RNA Biosignatures: A Paradigm Change for the Management of Young Febrile Infants$958,021
R01 · FY2019 · HD
High Precision System Analysis of Infant Immune Responses$522,868
U01 · FY2019 · AI · contact PI
Human Samples: Core C$388,923
P01 · FY2019 · AI · contact PI
Live Attenuated RSV Vaccine with Optimized Safety and Immunogenicity$1,488,538
P01 · FY2018 · AI
RNA Biosignatures: A Paradigm Change for the Management of Young Febrile Infants$1,140,513
R01 · FY2018 · HD
High Precision System Analysis of Infant Immune Responses$882,108
U01 · FY2018 · AI · contact PI
Human Samples: Core C$382,117
P01 · FY2018 · AI · contact PI
Live Attenuated RSV Vaccine with Optimized Safety and Immunogenicity DIVERSITY SUPPLEMENT$36,334
P01 · FY2018 · AI
Live Attenuated RSV Vaccine with Optimized Safety and Immunogenicity$1,487,635
P01 · FY2017 · AI
RNA Biosignatures: A Paradigm Change for the Management of Young Febrile Infants$1,364,123
R01 · FY2017 · HD
High Precision System Analysis of Infant Immune Responses$527,677
U01 · FY2017 · AI · contact PI
Human Samples: Core C$258,212
P01 · FY2017 · AI · contact PI
Live Attenuated RSV Vaccine with Optimized Safety and Immunogenicity$1,489,165
P01 · FY2016 · AI
RNA Biosignatures: A Paradigm Change for the Management of Young Febrile Infants$1,128,934
R01 · FY2016 · HD
Human Samples: Core C$343,637
P01 · FY2016 · AI · contact PI
RNA Biosignatures: A Paradigm Change for the Management of Young Febrile Infants$1,423,234
R01 · FY2015 · HD
Live Attenuated RSV Vaccine with Optimized Safety and Immunogenicity$749,998
P01 · FY2015 · AI
Human Samples: Core C$129,916
P01 · FY2015 · AI · contact PI
RNA Biosignatures in the Emergency Evaluation of Febrile Infants$553,848
R01 · FY2014 · HD
RNA Biosignatures in the Emergency Evaluation of Febrile Infants$545,914
R01 · FY2013 · HD
Clinical Core$205,569
U19 · FY2013 · AI · contact PI
RNA Biosignatures in the Emergency Evaluation of Febrile Infants$584,677
R01 · FY2012 · HD
Clinical Core$159,780
U19 · FY2012 · AI · contact PI
RNA Biosignatures in the Emergency Evaluation of Febrile Infants$643,595
R01 · FY2011 · HD
Clinical Core$297,992
U19 · FY2011 · AI · contact PI
RNA Biosignatures in the Emergency Evaluation of Febrile Infants$826,789
R01 · FY2010 · HD
Clinical Core$301,002
U19 · FY2010 · AI · contact PI
Clinical Core$306,069
U19 · FY2009 · AI · contact PI
Diagnosis of Infections in Humans with Microarrays$262,487
U19 · FY2008 · AI · contact PI
DENDRITIC CELLS, RSV AND INFLUENZA INFECTION IN CHILDREN$234,000
R21 · FY2005 · AI
DENDRITIC CELLS, RSV AND INFLUENZA INFECTION IN CHILDREN$234,000
R21 · FY2004 · AI